TAFAZZIN and cardiomyopathy: However, overexpressing catalase in Taz KD mice does not prevent cardiac dysfunction observed at 7–8 months of age [58], suggesting that resolving oxidative stress is not sufficient to suppress BTHS cardiomyopathy.